The CONTEMP-ICD trial is a prospective, multicenter, randomized controlled study designed to assess whether implantable cardioverter defibrillators (ICDs) remain necessary for primary prevention in patients with heart failure with reduced ejection fraction (HFrEF) who are receiving contemporary, guideline-directed medical therapy (GDMT). As modern pharmacologic and device-based treatments have significantly lowered the risk of sudden cardiac death in this population, CONTEMP-ICD investigates whether a non-ICD strategy is non-inferior to ICD implantation with respect to all-cause mortality. The trial will enroll 3,290 patients across 115 sites and will evaluate additional outcomes such as cardiovascular hospitalization, ICD-related complications, and healthcare utilization. The study design, rationale, and methodology are fully detailed in the article Reassessing the need for primary prevention implantable cardioverter-defibrillators in contemporary patients with heart failure—a link to which is available in the “Our Publications” section below.